arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

Verrica Pharmaceuticals Inc.

VRCA
$3.09 ▼ -0.40 (-11.46%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
39 Visible periods
30 Metrics
Peer-ranked Benchmarks
Price Chart
31
Health
Poor
Moderately Bearish
auto_awesome

Analytical Summary

Verrica Pharmaceuticals Inc. faces fundamental challenges with weakness in Return on Common Equity (%) and Profit Margin (%). On the positive side, Debt to Equity remains strong. Investors should exercise caution and monitor for improvement in key metrics.

Market Cap $65.8M
Dividend Yield —
Revenue Growth -53.8% ↘
Op. Margin -223.4% ↘
ROIC -240.2% ↘
FCF / Share $-0.44 →
Trailing P/E —
Price / Book 12.3x
FCF Yield —
Debt / Equity —
info Valuation on last close. End-of-day price, Nov 5, 2026.

39-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$5.86M
↓ -53.8% —
Net Income Profit after all expenses
$-9.68M
↑ +0.6% —
Operating Margin Operating profit as % of sales
-223.4%
↓ -15.5% 7th
FCF / Share Free cash flow per share
$-0.44
↓ -1.3% —
Long-Term Debt Long-term obligations
$0.00
↓ -100.0% —
trending_up

Bullish Indicators

  • Debt to EquityDebt to Equity is in the top quartile (lower is better)
warning

Bearish Risks

  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile
  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Profitability ↑
6
Returns ↓
12
Financial Health ↑
69
Cash Quality ↑
65

bar_chart Data from SEC EDGAR XBRL filings

Synced 4 days ago 10 years · 39 quarters